Deep Track Capital Portfolio
13F Holdings & Position Changes — Last filed May 15, 2026
13F Holdings & Position Changes — Last filed May 15, 2026
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Deep Track Capital is a $5B biotech-focused hedge fund managed by David Kroin. As of their latest 13F filing (Q1 2026), the fund holds 59 positions worth $4.7B. This quarter they initiated 8 new positions and exited 90. Their largest holding is GH ($308.4M).
Deep initiated 8 new positions and increased 30 this quarter. Portfolio grew +15.8% to $4.7B. 599 upcoming catalysts across holdings. 1 insider buy detected in portfolio companies.
Portfolio Value (13F)
$4.7B
Holdings
59
Top 10 Concentration
45.8%
QoQ Change
+15.8%
Turnover
7.1%
Portfolio Value Trend
Be first to know when Deep Track Capital files next quarter
Get an email the moment new buys, exits, and conviction changes hit. Free 14-day trial.
| # | Ticker | Company | Change | Value | % of Portfolio | SI % Float ? | Trend |
|---|---|---|---|---|---|---|---|
| 1 | GH | Guardant Health Inc. | Increased | $308.4M | 6.56% | 10.1% | |
| 2 | IMVT | Immunovant Inc. | $286.3M | 6.09% | 20.9% | ||
| 3 | TARS | Tarsus Pharmaceuticals Inc. | Increased↑5Q | $252.5M | 5.37% | 11.6% | |
| 4 | PCVX | Vaxcyte Inc. | Increased↑5Q | $249.9M | 5.32% | 9.8% | |
| 5 | GPCR | Structure Therapeutics Inc. | Increased | $206.3M | 4.39% | 11.5% | |
| 6 | AXSM | Axsome Therapeutics Inc. | Decreased | $185.9M | 3.95% | 8.4% | |
| 7 | APLS | Apellis Pharmaceuticals Inc. | Decreased↓2Q | $182.3M | 3.88% | 14.6% | |
| 8 | OCUL | Ocular Therapeutix Inc. | Increased | $166.7M | 3.55% | 13.4% | |
| 9 | VERA | Vera Therapeutics Inc. | Increased↑2Q | $165.2M | 3.51% | 14.9% | |
| 10 | ALMS | Alumis Inc. | New | $149.2M | 3.17% | 16.2% | — |
Share changes reflect active decisions. Value changes include price moves.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
No charge for 14 days · Cancel anytime
Deep Track Capital held 59 biotech stocks in their 13F portfolio this quarter. Their top positions include GH, IMVT, TARS, PCVX, GPCR. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
Deep Track Capital's tracked biotech portfolio is worth $4.7B across 59 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
Deep Track Capital initiated 8 new positions this quarter, including ALMS, DFTX, CRVS, MANE, SLDB and 3 more. They also increased 30 existing positions.
Deep Track Capital fully exited 90 positions this quarter, including DVAX, TXG, ABOS, INKT, ZNTL and 85 more. They also trimmed 13 existing positions.
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free Trial| 3,600,000 |
| $252.5M |
| 5.37% |
| 4 | PCVX | Vaxcyte Inc. | Increased | 4,300,000 | $249.9M | 5.32% |
| 5 | GPCR | Structure Therapeutics Inc. | Increased | 4,279,848 | $206.3M | 4.39% |
| 6 | AXSM | Axsome Therapeutics Inc. | Decreased | 1,100,000 | $185.9M | 3.95% |
| 7 | APLS | Apellis Pharmaceuticals Inc. | Decreased | 4,532,374 | $182.3M | 3.88% |
| 8 | OCUL | Ocular Therapeutix Inc. | Increased | 19,686,282 | $166.7M | 3.55% |
| 9 | VERA | Vera Therapeutics Inc. | Increased | 4,106,067 | $165.2M | 3.51% |
| 10 | ALMS | Alumis Inc. | New | 6,772,595 | $149.2M | 3.17% | — |
| 11 | IONS | Ionis Pharmaceuticals Inc. | Increased | 1,950,000 | $146.4M | 3.11% |
| 12 | NUVL | Nuvalent Inc. | Increased | 1,376,324 | $141.0M | 3.00% | — |
| 13 | ALKS | Alkermes plc | Increased | 3,590,323 | $127.0M | 2.70% |
| 14 | CNTA | Centessa Pharmaceuticals plc | Increased | 3,158,041 | $125.4M | 2.67% |
| 15 | MLTX | MoonLake Immunotherapeutics | Increased | 6,408,863 | $119.5M | 2.54% |
| 16 | MAZE | Maze Therapeutics, Inc. | Decreased | 3,477,562 | $103.8M | 2.21% |
| 17 | ORKA | Oruka Therapeutics, Inc. | Decreased | 2,034,203 | $99.8M | 2.12% |
| 18 | NRIX | Nurix Therapeutics Inc. | Decreased | 6,345,244 | $98.4M | 2.09% |
| 19 | CYTK | Cytokinetics Incorporated | Decreased | 1,374,320 | $90.6M | 1.93% |
| 20 | GRAL | Grail, Inc. | Increased | 1,722,797 | $89.0M | 1.89% |
| 21 | LBRX | LB Pharmaceuticals Inc. | 3,352,804 | $82.7M | 1.76% |
| 22 | MBX | MBX Biosciences, Inc. | Decreased | 2,757,569 | $82.3M | 1.75% |
| 23 | BCAX | Bicara Therapeutics Inc. | Increased | 4,062,500 | $80.8M | 1.72% |
| 24 | CMPS | COMPASS Pathways plc | Increased | 12,161,496 | $67.3M | 1.43% |
| 25 | BMRN | BioMarin Pharmaceutical Inc. | Decreased | 1,150,000 | $65.0M | 1.38% |
| 26 | BBIO | BridgeBio Pharma Inc. | Increased | 841,445 | $62.5M | 1.33% |
| 27 | IMCR | Immunocore Holdings plc | Decreased | 1,931,884 | $58.2M | 1.24% |
| 28 | TNGX | Tango Therapeutics Inc. | Increased | 2,750,000 | $57.5M | 1.22% |
| 29 | DFTX | Definium Therapeutics, Inc. | New | 3,000,000 | $56.7M | 1.21% | — |
| 30 | TERN | Terns Pharmaceuticals Inc. | Increased | 1,073,877 | $56.6M | 1.20% |
| 31 | GERN | Geron Corporation | Decreased | 31,720,278 | $47.3M | 1.01% |
| 32 | ANIP | Ani Pharmaceuticals Inc. | Increased | 600,000 | $46.1M | 0.98% |
| 33 | CRMD | CorMedix Inc. | Increased | 6,274,076 | $42.6M | 0.91% |
| 34 | ATAI | Atai Beckley N.V. | Increased | 12,000,000 | $42.5M | 0.90% |
| 35 | CLDX | Celldex Therapeutics Inc. | Decreased | 1,283,979 | $40.7M | 0.87% |
| 36 | COGT | Cogent Biosciences Inc. | Increased | 1,000,000 | $38.5M | 0.82% |
| 37 | CRVS | Corvus Pharmaceuticals Inc. | New | 2,491,539 | $36.5M | 0.78% | — |
| 38 | DYN | Dyne Therapeutics Inc. | Decreased | 2,000,000 | $36.3M | 0.77% |
| 39 | SLNO | Soleno Therapeutics Inc. | Increased | 1,078,710 | $36.1M | 0.77% |
| 40 | ACRS | Aclaris Therapeutics Inc. | Increased | 9,345,000 | $35.0M | 0.75% | — |
| 41 | MANE | Veradermics, Inc. | New | 500,000 | $31.6M | 0.67% | — |
| 42 | VSTM | Verastem, Inc. | 5,740,850 | $30.4M | 0.65% |
| 43 | ENGNW | enGene Holdings Inc. | 4,377,572 | $29.8M | 0.63% |
| 44 | XFOR | X4 Pharmaceuticals, Inc. | Increased | 6,339,535 | $26.2M | 0.56% |
| 45 | SLDB | Solid Biosciences Inc. | New | 3,565,062 | $25.7M | 0.55% | — |
| 46 | ENTA | Enanta Pharmaceuticals Inc. | 1,956,867 | $24.7M | 0.53% |
| 47 | APGE | Apogee Therapeutics Inc. | Increased | 285,000 | $24.0M | 0.51% |
| 48 | KURA | Kura Oncology, Inc. | Increased | 2,643,542 | $21.5M | 0.46% |
| 49 | IPSC | Century Therapeutics, Inc. | Increased | 9,487,745 | $21.4M | 0.46% | — |
| 50 | BEAM | Beam Therapeutics Inc. | Increased | 820,765 | $19.6M | 0.42% |
| 51 | PSNL | Personalis, Inc. | New | 3,000,000 | $19.1M | 0.41% | — |
| 52 | JANX | Janux Therapeutics Inc. | Increased | 1,187,290 | $16.5M | 0.35% |
| 53 | PMN | ProMIS Neurosciences Inc. | New | 835,655 | $10.6M | 0.23% | — |
| 54 | CBIO | Crescent Biopharma, Inc. | 453,686 | $8.3M | 0.18% |
| 55 | IVEVF | Inventiva S.A. | Increased | 1,222,453 | $6.8M | 0.14% |
| 56 | LRMR | Larimar Therapeutics, Inc. | New | 1,500,000 | $6.8M | 0.14% | — |
| 57 | HELP | Cybin Inc. | Decreased | 1,313,137 | $6.3M | 0.13% |
| 58 | BLLN | BillionToOne, Inc. | 50,000 | $3.9M | 0.08% |
| 59 | ALGS | Aligos Therapeutics, Inc. | 444,110 | $3.3M | 0.07% |
| Q3 2025 |
| $3.4B |
| 51 |
| +9 |
| -78 |
| +16.3% |
| Q2 2025 | $2.9B | 57 | +2 | -63 | -0.0% |
| Q1 2025 | $2.9B | 62 | +7 | -56 | +16.1% |
| Q4 2024 | $2.5B | 56 | +9 | -55 | -16.7% |
| Q3 2024 | $3.0B | 62 | +9 | -40 | -6.7% |
| Q2 2024 | $3.2B | 58 | +6 | -35 | +29.2% |
| Q1 2024 | $2.5B | 37 | +13 | — | — |